Potentially FCGR3B CNV can be used as a new biomarker for cancer immunotherapy, where patients can be stratified with likelihood of benefitting from therapy when patients have a lower FCGR3B CNV combined with the right tumor antigens (e.g., HER2/Neu or EGFR). This evidence concerns the gene ERBB2 and neoplasm.